[go: up one dir, main page]

WO1998016265B1 - Liquid embolic agents containing partially hydrolyzed polyvinyl acetate - Google Patents

Liquid embolic agents containing partially hydrolyzed polyvinyl acetate

Info

Publication number
WO1998016265B1
WO1998016265B1 PCT/US1997/018582 US9718582W WO9816265B1 WO 1998016265 B1 WO1998016265 B1 WO 1998016265B1 US 9718582 W US9718582 W US 9718582W WO 9816265 B1 WO9816265 B1 WO 9816265B1
Authority
WO
WIPO (PCT)
Prior art keywords
occludant
new
precursor composition
partially hydrolyzed
radio
Prior art date
Application number
PCT/US1997/018582
Other languages
French (fr)
Other versions
WO1998016265A1 (en
Filing date
Publication date
Priority claimed from US08/734,442 external-priority patent/US5925683A/en
Application filed filed Critical
Priority to EP97912731A priority Critical patent/EP0934086B1/en
Priority to JP51855298A priority patent/JP3804071B2/en
Priority to DE69735534T priority patent/DE69735534T2/en
Priority to AU49842/97A priority patent/AU4984297A/en
Publication of WO1998016265A1 publication Critical patent/WO1998016265A1/en
Publication of WO1998016265B1 publication Critical patent/WO1998016265B1/en
Priority to US09/291,853 priority patent/US6160025A/en

Links

Abstract

This relates to a composition of matter comprising partially hydrolyzed polyvinyl acetate solutions suitable for use as embolic agent precursors. In addition, a procedure for introducing the solutions into the human body to form precipitated embolic occlusion masses is shown. Finally, a procedure for treatment of hepatic tumors using portal vein embolism is described.

Claims

AMENDED CLAIMS[received by the International Bureau on 1 May 1998 (01.05.98); original claims 11 and 26 cancelled; original claims 1, 12, 15 and 27-29 amended; new claims 31-52 added; remaining claims unchanged (8 pages)]
1. An occludant precursor composition for forming an occlusion mass upon introduction of the precursor into a mammalian body comprising a solution of: a.) partially hydrolyzed polyvinylacetate, b.) a pharmaceutically acceptable solvent, and c.) a soluble radio-opaque material.
2. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10.000 to 500,000.
3. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50.000 to 100,000.
4. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
5. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
6. The occludant precursor composition of claim 5 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
20
7. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises ethanol.
8. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution.
9. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
10. The occludant precursor composition of claim 9 wherein the aqueous ethanolic solution contains 45-55% (vol) ethanol.
1 1. [cancelled]
12. The occludant precursor composition of claim 1 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide, and mixtures and solutions thereof.
13. The occludant precursor composition of claim 12 wherein the radio-opaque material comprises iopromide.
14. The occludant precursor composition of claim 12 wherein the radio-opaque material comprises metrizamide.
15. A method for occluding a selected site in a mammalian body comprising the steps of: a.) introducing to said selected site an occludant precursor composition for forming an occlusion mass, said precursor comprising a solution of: i) partially hydrolyzed polyvinylacetate. [and] ii.) a pharmaceutically acceptable solvent, iii.) a soluble radio-opaque material, and b.) releasing said occludant precursor composition at said selected site to form said occlusion mass.
16. The method of claim 15 wherein the introducing step is carried out using a tubular member.
17. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
18. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100.000.
19. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
20. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
22
21. The method of claim 15 wherein the composition contains between 7.5 and 30%(wf) of partially hydrolyzed polyvinylacetate.
22. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises ethanol.
23. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution.
24. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
25. The method of claim 24 wherein the aqueous ethanolic solution contains 45- 55% ethanol.
26. [cancelled]
27. The method of claim 15 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide, and mixtures and solutions thereof.
28. The method of claim 15 wherein the radio-opaque material comprises iopromide.
23
29. The method of claim 15 wherein the radio-opaque material comprises metrizamide.
30. The method of claim 15 wherein the tubular member is passed into the portal vein proximal of the liver.
31. (new) An occludant precursor composition for forming an occlusion mass upon introduction of the precursor into a mammalian body comprising a solution of: a.) partially hydrolyzed polyvinylacetate, and b.) a pharmaceutically acceptable solvent comprising an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
32. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
33. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100.000.
34. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
35. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the ranee of 2.3 to 5.6.
24
36. (new) The occludant precursor composition of claim 35 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
37. (new) The occludant precursor composition of claim 31 further comprising a radio-opaque material.
38. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises a material selected from the group consisting of iopromide, metrizamide, and mixtures and solutions thereof.
39. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises iopromide.
40. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises metrizamide.
41. (new) A method for occluding a selected site in a mammalian body comprising the steps of: a.) introducing to said selected site an occludant precursor composition for forming an occlusion mass, said precursor comprising a solution of: i) partially hydrolyzed polyvinylacetate, and ii.) a pharmaceutically acceptable solvent comprising an aqueous ethanolic solution containing 30 to 55%(vol) ethanol, and b.) releasing said occludant precursor composition to form said occlusion mass.
42. (new) The method of claim 41 wherein the introducing step is carried out using a tubular member.
25
43. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
44. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100,000.
45. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
46. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
47. (new) The method of claim 41 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
48. (new) The method of claim 41 wherein the composition further comprises a radio-opaque material.
49. (new) The method of claim 48 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide. and mixtures and solutions thereof.
50. (new) The method of claim 48 wherein the radio-opaque material comprises iopromide.
26
51. (new) The method of claim 48 wherein the radio-opaque material comprises metrizamide.
52. (new) The method of claim 41 wherein the tubular member is passed into the portal vein proximal of the liver.
27 STATEMENT UNDER ARTICLE 19
This in response to the International Search Report mailed 3/3/98. In this Amendment, claims 1 1 and 26 have been cancelled and new claims 31 through 52 have been added. Consequently, claims 1 -10, 12-25. and 27-52 are under consideration. Reconsideration is requested.
28
PCT/US1997/018582 1996-10-17 1997-10-15 Liquid embolic agents containing partially hydrolyzed polyvinyl acetate WO1998016265A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97912731A EP0934086B1 (en) 1996-10-17 1997-10-15 Liquid embolic agents containing partially hydrolyzed polyvinyl acetate
JP51855298A JP3804071B2 (en) 1996-10-17 1997-10-15 Liquid embolic agent containing partially hydrolyzed polyvinyl acetate
DE69735534T DE69735534T2 (en) 1996-10-17 1997-10-15 LIQUID EMBOLIZING AGENTS OF PARTIALLY HYDROLYZED POLYVINYL ACETATE
AU49842/97A AU4984297A (en) 1996-10-17 1997-10-15 Liquid embolic agents containing partially hydrolyzed polyvinyl acetate
US09/291,853 US6160025A (en) 1996-10-17 1999-04-14 Liquid embolic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/734,442 1996-10-17
US08/734,442 US5925683A (en) 1996-10-17 1996-10-17 Liquid embolic agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/734,442 Continuation-In-Part US5925683A (en) 1996-10-17 1996-10-17 Liquid embolic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/291,853 Continuation US6160025A (en) 1996-10-17 1999-04-14 Liquid embolic agents

Publications (2)

Publication Number Publication Date
WO1998016265A1 WO1998016265A1 (en) 1998-04-23
WO1998016265B1 true WO1998016265B1 (en) 1998-06-18

Family

ID=24951721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018582 WO1998016265A1 (en) 1996-10-17 1997-10-15 Liquid embolic agents containing partially hydrolyzed polyvinyl acetate

Country Status (6)

Country Link
US (2) US5925683A (en)
EP (1) EP0934086B1 (en)
JP (1) JP3804071B2 (en)
AU (1) AU4984297A (en)
DE (1) DE69735534T2 (en)
WO (1) WO1998016265A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4127960B2 (en) 1997-08-05 2008-07-30 ボストン サイエンティフィック リミテッド Detachable aneurysm neck bridge
US6063070A (en) 1997-08-05 2000-05-16 Target Therapeutics, Inc. Detachable aneurysm neck bridge (II)
US6146373A (en) * 1997-10-17 2000-11-14 Micro Therapeutics, Inc. Catheter system and method for injection of a liquid embolic composition and a solidification agent
US6511468B1 (en) 1997-10-17 2003-01-28 Micro Therapeutics, Inc. Device and method for controlling injection of liquid embolic composition
WO2000013593A1 (en) 1998-09-04 2000-03-16 Boston Scientific Limited (Incorporated In Ireland) Detachable aneurysm neck closure patch
FR2784580B1 (en) * 1998-10-16 2004-06-25 Biosepra Inc POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME
WO2001003666A2 (en) * 1999-07-12 2001-01-18 Scimed Life Systems, Inc. Liquid based vaso-occlusive compositions
US6346098B1 (en) 2000-03-07 2002-02-12 The Board Of Trustees Of The Leland Stanford Junior University Methods and kits for locally administering an active agent to an interstitial space of a host
ATE373682T1 (en) 2000-03-13 2007-10-15 Biocure Inc EMBOLIC COMPOSITIONS
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
EP1267839B1 (en) * 2000-03-24 2007-10-03 Biosphere Medical, Inc. Microspheres for active embolization
US6729356B1 (en) * 2000-04-27 2004-05-04 Endovascular Technologies, Inc. Endovascular graft for providing a seal with vasculature
US6658288B1 (en) 2000-05-05 2003-12-02 Endovascular Technologies, Inc. Apparatus and method for aiding thrombosis through the application of electric potential
DE10117099A1 (en) * 2000-08-02 2002-02-21 Aesculap Ag & Co Kg Medical technology product, process for its production and provision for surgery
DE50111415D1 (en) * 2000-08-02 2006-12-21 Aesculap Ag & Co Kg MEDICAL TECHNICAL PRODUCT, METHOD FOR THE PRODUCTION AND PROVISION OF SURGERY
EP1381420A2 (en) * 2001-04-26 2004-01-21 Christopher H. Porter Method and apparatus for delivering materials to the body
WO2002089676A2 (en) * 2001-05-04 2002-11-14 Concentric Medical Hydrogel filament vaso-occlusive device
AU2002340749A1 (en) * 2001-05-04 2002-11-18 Concentric Medical Coated combination vaso-occlusive device
EP1392182A1 (en) * 2001-05-04 2004-03-03 Concentric Medical Hydrogel vaso-occlusive device
US6685745B2 (en) * 2001-05-15 2004-02-03 Scimed Life Systems, Inc. Delivering an agent to a patient's body
US7687053B2 (en) * 2001-08-20 2010-03-30 Boston Scientific Scimed, Inc. Embolic compositions with non-cyanoacrylate rheology modifying agents
US20030050635A1 (en) * 2001-08-22 2003-03-13 Csaba Truckai Embolization systems and techniques for treating tumors
US6911219B2 (en) * 2001-09-27 2005-06-28 Surgica Corporation Partially acetalized polyvinyl alcohol embolization particles, compositions containing those particles and methods of making and using them
WO2003037191A1 (en) * 2001-10-26 2003-05-08 Concentric Medical Device for vaso-occlusion
US7341716B2 (en) * 2002-04-12 2008-03-11 Boston Scientific Scimed, Inc. Occlusive composition
CA2503949C (en) * 2002-10-29 2012-10-23 Toray Industries, Inc. Embolization material
HUP0203719A2 (en) * 2002-10-31 2007-09-28 Stepan Dr Gudak Polyuretan composition for fillin blood vessels and method of aplication of it
US20040115164A1 (en) * 2002-12-17 2004-06-17 Pierce Ryan K. Soft filament occlusive device delivery system
DE602004020874D1 (en) * 2003-03-07 2009-06-10 Micro Therapeutics Inc COMPOSITIONS CONTAINED HIGH CONCENTRATION OF CONTRAST ELEMENTS FOR EMBOLIZING BLOOD CONTAINERS
US20050209674A1 (en) * 2003-09-05 2005-09-22 Kutscher Tuvia D Balloon assembly (V)
US20050090804A1 (en) * 2003-10-22 2005-04-28 Trivascular, Inc. Endoluminal prosthesis endoleak management
US20050283182A1 (en) * 2004-06-21 2005-12-22 Concentric Medical, Inc. Systems and methods for intraluminal delivery of occlusive elements
MX2007013914A (en) * 2005-05-09 2008-02-22 Biosphere Medical S A Compositions and methods using microspheres and non-ionic contrast agents.
BRPI0617652A2 (en) * 2005-10-19 2011-08-02 Pulsar Vascular Inc methods and systems for endovascular incision and repair of tissue and lumen defects
US8545530B2 (en) * 2005-10-19 2013-10-01 Pulsar Vascular, Inc. Implantable aneurysm closure systems and methods
EP1986707A2 (en) 2006-01-30 2008-11-05 Surgica Corporation Compressible intravascular embolization particles and related methods and delivery systems
US20080039890A1 (en) * 2006-01-30 2008-02-14 Surgica Corporation Porous intravascular embolization particles and related methods
US7442105B2 (en) * 2006-05-05 2008-10-28 Freleng Safety Products, Llc Personal visibility marker
US9717584B2 (en) * 2007-04-13 2017-08-01 W. L. Gore & Associates, Inc. Medical apparatus and method of making the same
US20080255678A1 (en) * 2007-04-13 2008-10-16 Cully Edward H Medical apparatus and method of making the same
US9642693B2 (en) * 2007-04-13 2017-05-09 W. L. Gore & Associates, Inc. Medical apparatus and method of making the same
CN102202585B (en) * 2008-09-05 2014-04-02 帕尔萨脉管公司 Systems and methods for supporting or occluding a physiological opening or cavity
WO2010062678A2 (en) * 2008-10-30 2010-06-03 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
ES2651438T3 (en) 2009-09-04 2018-01-26 Pulsar Vascular, Inc. Systems to enclose an anatomical opening
JP6563192B2 (en) 2011-06-03 2019-08-21 パルサー バスキュラー インコーポレイテッド Aneurysm device and aneurysm treatment system
CA2837420C (en) 2011-06-03 2019-07-09 Pulsar Vascular, Inc. Aneurysm devices with additional anchoring mechanisms and associated systems and methods
CA2850783C (en) 2011-10-05 2020-01-07 Pulsar Vascular, Inc. Devices, systems and methods for enclosing an anatomical opening
JP6411331B2 (en) 2012-05-10 2018-10-24 パルサー バスキュラー インコーポレイテッド Aneurysm device with coil
CN102764456B (en) * 2012-07-24 2014-10-15 上海交通大学 Vascular occlusive agent, application thereof and preparation method
CN111840265B (en) * 2019-04-29 2023-06-16 李学义 Ethanol hardener and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2160503A (en) * 1936-02-14 1939-05-30 Chemische Forschungs Gmbh Blood stancher
US2657201A (en) * 1949-11-25 1953-10-27 Du Pont Controlled, heterogeneous hydrolysis of polymeric esters
NL153083B (en) * 1969-06-27 1977-05-16 Nijegaard & Co A S PROCESS FOR PREPARING TRIJODENZOIC ACID AMIDES.
DE2909439A1 (en) * 1979-03-08 1980-09-18 Schering Ag NEW NON-ionic x-ray contrast agents
US4631188A (en) * 1983-08-31 1986-12-23 S.K.Y. Polymers, Ltd. (Kingston Technologies) Injectable physiologically-acceptable polymeric composition
US4739768B2 (en) * 1986-06-02 1995-10-24 Target Therapeutics Inc Catheter for guide-wire tracking
GB8900376D0 (en) * 1989-01-09 1989-03-08 Nycomed As Iodinated esters
ATE130517T1 (en) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd INTRAVASCULAR EMBOLIZING AGENT CONTAINING A SUBSTANCE INHIBITING ANGIOGENESIS.
US5690666A (en) * 1992-11-18 1997-11-25 Target Therapeutics, Inc. Ultrasoft embolism coils and process for using them
US5443454A (en) * 1992-12-09 1995-08-22 Terumo Kabushiki Kaisha Catheter for embolectomy
US6296632B1 (en) * 1994-08-17 2001-10-02 Boston Scientific Corporation Ball-shaped fiber implant, and method and device for inserting the implant
US5749894A (en) * 1996-01-18 1998-05-12 Target Therapeutics, Inc. Aneurysm closure method
US5702361A (en) * 1996-01-31 1997-12-30 Micro Therapeutics, Inc. Method for embolizing blood vessels

Similar Documents

Publication Publication Date Title
WO1998016265B1 (en) Liquid embolic agents containing partially hydrolyzed polyvinyl acetate
EP2347770B2 (en) Process for producing an injectable pharmaceutical preparation
CA2060652A1 (en) N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives
US4054736A (en) Clathrate compounds of prostaglandins or their analogues with cyclodextrin
CA2198917A1 (en) Sustained release of peptides from pharmaceutical compositions
CH619614A5 (en)
CH629475A5 (en) METHOD FOR PRODUCING POLYPEPTIDES.
DE59010706D1 (en) Bile acid derivatives, process for their preparation, use as medicines
ATE49886T1 (en) NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND PROCESSES FOR THEIR MANUFACTURE.
CA2212856A1 (en) Benzopyran-containing compounds and method for their use
TW329386B (en) Cough medicine
IE881017L (en) Novel 2ß-morpholino-androstane derivatives and processes for¹their preparation
JPH05503940A (en) Novel insulin composition
Chatt et al. Chemical evidence concerning the function of molybdenum in nitrogenase
DE69829880T2 (en) CONJUGATE CONTAINS TWO ACTIVE SUBSTANCES
WO1996001634B1 (en) Long-acting oxytetracycline composition
DE69001734T2 (en) AMUSULOSIN PREPARATION TO BE USED EXTERNALLY.
EP0383346A3 (en) Catalyst, process for its preparation and process for polymerization of olefins using this catalyst
Colonna et al. Large scale HELP synthesis of oligodeoxynucleotides by the hydroxybenzotriazole phosphotriester approach.
CA2249753A1 (en) Improved process for the synthesis of alkylpolyglucosides
WO2001032680A3 (en) 18-nor-steroids as selectively active estrogens
WO1999005103A3 (en) 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent
ATE30231T1 (en) 3-BETA-(3'-(CARBOXYPROPIONYLOXY))-URSA-9(11),12 DIENE-28-CARBONIC ACID AND ITS SALTS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS.
EP0361317A3 (en) Pyridoindole derivatives and processes for preparation thereof
CA1136550A (en) Pharmaceutical composition containing thymidine